Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab in Advanced Penile Squamous Cell Carcinoma
NCT04231981Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of retifanlimab in penile squamous cell carcinoma (PSCC), sponsored by MEDSIR. Started Apr 2020; status: completed.
02
Drugs
retifanlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT04231981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231981.